Strategies For Maximizing Market Access
The launch of innovative health care products now calls for a multifaceted approach from pharma and medtech manufacturers as they develop their go-to-market plans. And in a payor climate that still favors efficacy over innovation, companies should constantly review methods of improving their success rates.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.